The U.S. compounding pharmacy market is projected to grow from USD 4.68 billion in 2025 to USD 7.41 billion by 2035, expanding at a CAGR of 4.7%, fueled by increasing demand for personalized medications , specialty therapies, and rising chronic health conditions.

U.S. Compounding Pharmacy Market Statical Scope

The U.S. compounding pharmacy market is witnessing robust growth, driven by a rising demand for personalized medications that cater to individual patient needs. Compounding pharmacies have emerged as critical players in addressing unique medical requirements inadequately met by standardized pharmaceutical products, particularly as healthcare trends shift towards customized treatment solutions.

The increasing prevalence of chronic pain among the elderly population further amplifies the demand for compounded medications tailored to manage pain within this demographic. Additionally, shortages of various drugs, including emergency medications and cancer treatments, are predicted to heighten demand for services offered by compounding pharmacies over the impending forecast period.

U.S. Compounding Pharmacy Market Share, By Therapeutic Area, 2025 (%)

• Pain management- the pain management segment dominates the market, accounting for 24%, driven by increasing prevalence of chronic pain conditions, rising demand for personalized pain therapies, and rising adoption of customized medication solutions.
• Specialty drugs- the specialty drugs segment held 20% of the market, supported by increasing use of patient-specific formulations and compounded therapies for complex medical conditions.
• Hormone replacement therapy- the hormone replacement therapy segment captured 18%, driven by rising awareness regarding hormonal health and increasing preference for customized hormone formulations.

U.S. Compounding Pharmacy Market Share, By Age Cohort, 2025 (%)

• Adults- the adults segment dominated the market, accounting for 52%, driven by the high prevalence of chronic diseases and the growing demand for customized treatment solutions.
• Geriatric- Geriatric patients segment held 30% of the market, supported by the increasing aging population and rising need for dosage-adjusted medication therapies.
• Pediatric- the pediatric patients segment accounted for 18%, driven by increasing requirements for child-friendly dosage forms and specialized pediatric formulations.

U.S. Compounding Pharmacy Market Share, By Compounding Type, 2025 (%)

• Pharmaceutical ingredient alteration (PIA)- The pharmaceutical ingredient alteration (PIA) segment dominated the market, accounting for 34%, driven by increasing demand for customized active ingredient formulations and patient-specific treatmen
• Currently unavailable pharmaceutical manufacturing (CUPM)- Currently unavailable pharmaceutical manufacturing (CUPM) segment held 27%, supported by increasing drug shortages and rising demand for compounded substitutes for unavailable medications.
• Pharmaceutical dosage alteration (PDA)- The Pharmaceutical dosage alteration (PDA) segment contributed 25% share, driven by the growing need for customized dosage strengths and alternative dosage forms.

U.S. Compounding Pharmacy Market Share, By Sterility, 2025 (%)

• Non-sterile- the non-sterile compounding segment dominated the market, accounting for 58%, driven by high demand for oral medicines, topical creams, and nutritional supplement formulations.
• Sterile- Sterile compounding held 42%, supported by increasing use of injectable medications, ophthalmic products, and hospital-based compounded therapies.

Competitive Landscape

The competitive landscape within the compounding pharmacy market comprises a blend of large-scale, well-established players and smaller, independent pharmacies. Key industry participants are consistently engaged in developing new opportunities within the healthcare sector. The top four players, B. Braun, Fagron, Fresenius Kabi, and Baxter, dominate the market, collectively accounting for approximately 35% to 40% of market share due to their extensive product offerings, advanced compounding technologies, and robust distribution networks. Industry participants are leveraging both organic and inorganic growth strategies to capture significant market share and outperform competitors, with major strategies including new product launches, partnerships, and expansion initiatives.

Recent Development in the Market

• In January 2026, Kazmira Therapeutics announced the official launch of the first licensed, prescription-only cannabinoid pharmacy, Kazmira Pharmacy. This LegitScript-certified 503A compounding pharmacy specializes in pure compounded cannabidiol (CBD) that contains no trace of tetrahydrocannabinol (THC), the psychoactive component found in hemp.
• In January 2026, industry leaders reiterated the necessity for compliance with specific conditions for compounded drugs to qualify for exemptions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Segments Covered in the Report

By Therapeutic Area

• Hormone replacement therapy
• Pain management
• Dermatology
• Specialty drugs
• Nutritional Supplements
• Others

By Age Cohort

• Pediatric
• Adult
• Geriatric

By Compounding Type

• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)
• Others

By Sterility

• Sterile
• Non Sterile